The prescription blood-thinner market is largely a zero-sum game. That explains why shares of Sanofi-Aventis — which sells the popular blood-thinner Plavix — are
in European trading, after reports late yesterday of a delay for a would-be rival.
The rival is prasugrel, which is being developed by Eli Lilly and Daiichi Sankyo. The
, part of a widely read family of biomed biz publications, reported yesterday that the application to Read the rest of this entry »